Xilio Therapeutics, Inc. (XLO) stock
XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3075% below fair value
$8.07−0.17 (-2.00%)
Close on Nov 13, 2026Market cap $46.69MP/E –Yield –
Xilio Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Xilio Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$39.87M. For fiscal 2025 it was -$40.44M. The highest annual figure on record is -$40.44M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$40.44M | – |
| FY2024 | Dec 31, 2024 | -$58.94M | – |
| FY2023 | Dec 31, 2023 | -$77.23M | – |
| FY2022 | Dec 31, 2022 | -$87.30M | – |
| FY2021 | Dec 31, 2021 | -$73.55M | – |
| FY2020 | Dec 31, 2020 | -$53.50M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$11.43M | – |
| Q2 FY2026 | Jun 30, 2026 | -$3.16M | – |
| Q1 FY2026 | Mar 31, 2026 | -$13.77M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.51M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.59M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.99M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.35M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.25M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.38M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.26M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.04M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.68M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.90M | – |
| Q2 FY2023 | Jun 30, 2023 | -$19.62M | – |
| Q1 FY2023 | Mar 31, 2023 | -$23.03M | – |
| Q4 FY2022 | Dec 31, 2022 | -$22.68M | – |
| Q3 FY2022 | Sep 30, 2022 | -$19.73M | – |
| Q2 FY2022 | Jun 30, 2022 | -$24.11M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.78M | – |
| Q4 FY2021 | Dec 31, 2021 | -$19.16M | – |
| Q3 FY2021 | Sep 30, 2021 | -$15.58M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.63M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.17M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.25M | – |
See a number that looks wrong?